Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 M^pro, Impairing Variants Replication In Vitro and In Vivo

• Main Authors: Otávio Augusto Chaves (Author), Carolina Q. Sacramento (Author), André C. Ferreira (Author), Mayara Mattos (Author), Natalia Fintelman-Rodrigues (Author), Jairo R. Temerozo (Author), Leonardo Vazquez (Author), Douglas Pereira Pinto (Author), Gabriel P. E. da Silveira (Author), Laís Bastos da Fonseca (Author), Heliana Martins Pereira (Author), Aluana Santana Carlos (Author), Joana C. d'Avila (Author), João P. B. Viola (Author), Robson Q. Monteiro (Author), Patrícia T. Bozza (Author), Hugo Caire Castro- (Author), Thiago Moreno L. Souza (Author)
• Format: Book
• Published: MDPI AG, 2021-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Atazanavir (ATV) has already been considered as a potential repurposing drug to 2019 coronavirus disease (COVID-19); however, there are controversial reports on its mechanism of action and effectiveness as anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Through the pre-clinical ch...